3. Schopfer DW, Ku IA, Regan M, et al. Growth differentiation factor 15 and cardiovascular events in patients with stable ischemic heart disease (The Heart and Soul Study). Am Heart J, 2014, 167(2): 186-192.
7. Azhar M, Schultz Jel J, Grupp I, et al. Transforming growth factor beta in cardiovascular development and function. Cytokine Growth Factor Rev, 2003, 14(5): 391-407.
[5]
8. Kempf T, Zarbock A, Widera C, et al. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med, 2011, 17(5): 581-588.
[6]
9. Bootcov MR, Bauskin AR, Valenzuela SM, et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci USA, 1997, 94(21): 11514-11519.
[7]
10. Xu J, Kimball TR, Lorenz JN, et al. GDF-15/MIC-1 function as a protective antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res, 2006, 98(3): 342-350.
[8]
11. Nickel N, Jonigk D, Kempf T, et al. GDF-15 is abundantly expressed in plexiform lesions in patients with pulmonary arterial hypertension and affects proliferation and apoptosis of pulmonary endothelial cells. Respir Res, 2011, 12(1): 62.
[9]
12. Frank D, Kulm C, Brors B, et al. Gene expression pattern in biomechanically stretched cardiomyocytes: evidence for a stretch-specific gene program. Hypertension, 2008, 51(2): 309-318.
[10]
13. Clerk A, Kenp TJ, Zoumpoulidon G, et al. Cardiac myocyte gene expression profiling during H2O2-induced apoptosis. Physiol Genomics, 2007, 29(2): 118-127.
[11]
14. Brown DA, Breit SN, Buring J, et al. Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. Lancet, 2002, 359(9324): 2159-2163.
[12]
15. Lankeit M, Kempf T, Dellas C, et al. Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism. Am J Respir Crit Care Med, 2008, 177(9): 1018-1025.
[13]
18. Guidelines on diagnosis and management of acute pulmonary embolism. Task Force on Pulmonary Embolism, European Society of Cardiology. Eur Heart J, 2000, 21(16): 1301-1336.
[14]
19. Watts JA, Gellar MA, Stuart L, et al. Effects of angiotensin (1-7) upon right ventricular function in experimental rat pulmonary embolism. Histol Histopathol, 2011, 26(10): 1287-1294.
[15]
20. Nickel N, Kempf T, Tapken H, et al. Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med, 2008, 178(5): 534-541.
[16]
21. Lind L, Wallentin L, Kempf T, et al. Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. Eur Heart J, 2009, 30(19): 2346-2353.
23. Duran L, Kayhan S, Guzel A, et al. The prognostic values of GDF-15 in comparison with NT-proBNP in patients with normotesive acute pulmonary embolism. Clin Lab, 2014, 60(8): 1365-1371.
